Research grade

COA available

GLP / Metabolic

Cagrilintide 5mg

Synthetic long-acting amylin analog — 37 amino acids with acylated C18 fatty diacid modification Targets AMY1, AMY2, and AMY3 receptor subtypes Research-grade · Lyophilized powder For in vitro amylin receptor research only

$53.99 In stock

SSL 256-bit Secure Checkout

Same-day dispatch on orders before 12:00 PM ET, Mon–Fri. Discreet, plain packaging.

View this compound’s Certificate of Analysis →

For laboratory research use only. Not for human or veterinary consumption. SKU CGL5.

Overview

Product details.

Cagrilintide 5mg — Long-Acting Amylin Analog

Amylin is co-secreted with insulin from pancreatic beta cells, but its receptor system is entirely separate — and more complex than most. Amylin receptors (AMY1, AMY2, AMY3) are heterodimers: a calcitonin receptor (CTR) paired with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Each combination produces a distinct binding profile and downstream signaling cascade. Cagrilintide is a 37-amino-acid synthetic analog engineered to engage these receptors with an extended duration of action courtesy of C18 fatty diacid acylation.

Research-Grade Compounds

Manufactured to research-grade standards for laboratory research use only.

Discreet Shipping

Every order ships in plain, protective packaging.

In-House Fulfillment

Orders are inspected, packed, and shipped directly by the Heritage Labs team.

Specifications

Amino Acids	37
Classification	Long-acting amylin receptor agonist
Modification	C18 fatty diacid acylation for albumin binding
Molecular Weight	~4,034 Da (acylated form)
CAS Number	2196070-45-4
Purity	Research-grade
Form	Lyophilized powder
Quantity	5mg per vial

Molecular Design and Albumin Binding

Native human amylin (islet amyloid polypeptide, IAPP) has a circulating half-life measured in minutes, limiting its utility in sustained-exposure research models. Cagrilintide addresses this through C18 fatty diacid acylation — a lipidation strategy that enables reversible, non-covalent binding to serum albumin. This albumin association creates a circulating depot effect, substantially extending the pharmacokinetic profile compared to unmodified amylin. The approach is conceptually related to the Drug Affinity Complex (DAC) used in CJC-1295, though the underlying chemistry differs. Lau et al. described the design rationale for acylated amylin analogs in the context of sustained receptor engagement (Lau et al., Journal of Medicinal Chemistry, 2015; PubMed 26288685).

Amylin Receptor Pharmacology

The amylin receptor system represents one of the more intricate GPCR signaling networks studied in metabolic research. The three receptor subtypes — AMY1 (CTR + RAMP1), AMY2 (CTR + RAMP2), and AMY3 (CTR + RAMP3) — each exhibit distinct ligand affinity profiles and tissue distribution patterns. Cagrilintide has been investigated for its binding characteristics across all three subtypes. Downstream signaling involves cAMP accumulation through Gαs coupling, with additional contributions from β-arrestin recruitment and receptor internalization pathways (Hay et al., Pharmacological Reviews, 2015; PubMed 26023145). Understanding subtype-selective signaling is a key area of ongoing amylin receptor research.

Published Research and Preclinical Data

Cagrilintide has been examined in multiple preclinical contexts. Lau et al. demonstrated that long-acting amylin analogs produce sustained receptor activation in rodent models, enabling researchers to study the physiological consequences of prolonged amylin signaling rather than the brief, pulsatile exposure that native IAPP provides (PubMed 26288685). Separate investigations have explored cagrilintide in combination with semaglutide (a GLP-1 receptor agonist), examining the distinct but complementary signaling pathways activated by amylin and GLP-1 receptor engagement in area postrema and hypothalamic circuits (Enebo et al., The Lancet, 2021; PubMed 34004180).

Research Applications

Amylin receptor subtype (AMY1/2/3) binding selectivity and signaling bias studies
CTR/RAMP heterodimer formation and modulation research
Acylated peptide pharmacokinetics — albumin binding dynamics and depot release modeling
Comparative structure-activity analysis of amylin analogs (pramlintide, native IAPP, cagrilintide)
Dual-pathway investigation pairing amylin receptor agonism with GLP-1 or GIP receptor activation
Area postrema and hindbrain neuronal circuit mapping in metabolic signaling models

Frequently Paired With

SM1 5mg — Enables dual-pathway investigation: amylin signaling through hindbrain circuits alongside GLP-1 receptor engagement through hypothalamic pathways.

Quality and testing

Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.

Storage

Lyophilized: Store at -20°C, protected from light and moisture
Reconstituted: 2-8°C, use within 30 days
Avoid repeated freeze-thaw cycles

References

Lau J, et al. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. PubMed 26288685
Hay DL, et al. Pharmacological Reviews. 2015;67(3):564-600. PubMed 26023145
Enebo LB, et al. The Lancet. 2021;397(10286):1736-1748. PubMed 34004180

For laboratory research use only. Not for human or veterinary use.

For laboratory research use only. Not for human or veterinary use. This product is not a drug or supplement and is not intended to diagnose, treat, cure, or prevent any disease.

FDA Disclaimer. All products are for research use only (RUO) as defined by the FDA — not for diagnostic, human, or veterinary use. These products have not been evaluated and have not been approved by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

Heritage Labs is a chemical supplier providing products strictly for laboratory research, analytical, and in-vitro purposes; it is not a compounding pharmacy or compounding facility under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act.